跳至主要内容
临床试验/NCT02159079
NCT02159079已完成不适用

A Phase II/III Randomized Controlled Trial of a Conservative Fluid Balance Strategy for Patients With Sepsis and Cardiopulmonary Dysfunction

Vanderbilt University2 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2014年7月最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
30
试验地点
2
主要终点
ICU-free Days to 14 Days After Enrollment

研究概览

简要总结

Sepsis is a common inflammatory response to infection characterized by hypovolemia and vasodilation for which early administration of intravenous fluids has been suggested to improve outcomes. The ideal fluid balance following initial resuscitation is unclear. Septic patients treated in the intensive care unit commonly receive significant volumes of intravenous fluids with resultant positive fluid balance for up to a week after their initial resuscitation. Observational studies have associated fluid receipt and positive fluid balance in patients with severe sepsis and septic shock with increased mortality but are inherently limited by indication bias. In order to determine the optimal approach to fluid management following resuscitation in patients with severe sepsis and septic shock, a randomized controlled trial is needed. The primary hypothesis of this study is that, compared to usual care, a conservative approach to fluid management after resuscitation in patients with sepsis and cardiopulmonary dysfunction will increase intensive care unit free days.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • ICU patients
  • Sepsis as defined by at least two systemic inflammatory response syndrome criteria and receipt of antimicrobial therapy
  • Cardiopulmonary dysfunction as defined shock or respiratory failure

排除标准

  • Inability to obtain consent
  • Greater than 48 hours since inclusion criteria initially met
  • Allergy to furosemide AND bumetanide
  • Rhabdomyolysis with creatinine kinase > 5000 U/L
  • Hypercalcemia with calcium >11 mg/dL
  • Diabetic Ketoacidosis requiring continuous insulin infusion
  • Tumor Lysis Syndrome diagnosed clinically
  • Pancreatitis diagnosed clinically
  • Chronic Hypoxic Respiratory Failure with Home Oxygen Use of FiO2≥0.3
  • Chronic ventilator dependence
  • cervical spinal cord injury at level C5 or higher
  • amyotrophic lateral sclerosis
  • Guillain-Barré Syndrome
  • myasthenia gravis
  • Renal failure requiring renal replacement therapy
  • Burns >20% of body surface area
  • Preexisting pulmonary hypertension with PAPmean>40 on RHC
  • Severe chronic liver disease with Childs-Pugh Score >11
  • Moribund and not expected to survive an additional 24 hours
  • Actively withdrawing life support or transitioning to comfort measures only
  • Unwillingness of treating physician to employ conservative fluid strategy

研究组 & 干预措施

Usual Care

No Intervention

Patients in the usual care arm will be managed exclusively by their treating clinician without input from study personnel.

Conservative Fluid Management Strategy

Experimental

For patients in the conservative fluid management arm, beginning 12 hours after admission to study ICU and ending at the first of ICU discharge, death, return to home inspired oxygen, or study day 14, fluid management will be controlled by a study protocol. Patients in shock will receive fluid boluses only as specified by the protocol for oliguria and rapidly increasing vasopressor requirement. Patients not in shock will receive fluid boluses only as specified by the protocol for oliguria. Output will exceed input each day using a diuretic drip if required. Study protocol will be held only for pre-specified Safety Endpoints of persistent oliguria, decompensating shock, diuretic side effect, and intervening acute event.

干预措施: Conservative Fluid Management Strategy (Other)

结局指标

主要结局

ICU-free Days to 14 Days After Enrollment

时间窗: 14 days

The primary outcome will be the number of ICU-free days to day 14 (defined as the number days alive and outside of the intensive care unit in the first 14 days after enrollment).

次要结局

  • Renal Replacement Therapy-free Days to Day 14(14 days)
  • Highest Plasma Creatinine Between Enrollment and 28 Days After Enrollment(28 days)
  • In-hospital Mortality to Day 14(14 days)
  • Highest Stage of Acute Kidney Injury(28 days)
  • Ventilator-free Days to Day 14(14 days)
  • Receipt of Renal Replacement Therapy(28 days)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Matthew Semler

Fellow in Pulmonary and Critical Care Medicine

Vanderbilt University

研究点 (2)

Loading locations...

相似试验